Back to search

Article

Gemcitabine plus Oxaliplatin (GEMOX) combined with Atezolizumab and Bevacizumab for Advanced Biliary Tract Cancer: A Preliminary Observational Study

2022-10-18

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>Anti-PD-L1/VEGF inhibition, coupled with chemotherapy, may potentiate antitumor immunity leading to enhanced clinical benefit, but it has not been investigated in advanced biliary tract cancer (BTC). We investigated the efficacy and safety of gemcitabine plus oxaliplatin (GEMOX) combined with atezolizumab and bevacizumab for advanced BTC and explore the potentia...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f284e21b-ed1e-519e-9466-f565ff9d3dc6
DOI
10.21203/rs.3.rs-2149321/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Gemcitabine plus Oxaliplatin (GEMOX) combined with Atezolizumab and Bevacizumab for Advanced Biliary Tract Cancer: A Preliminary Observational StudyDOI 10.21203/rs.3.rs-2149321/v1
Chemotherapy and targeted therapy for advanced biliary tract cancers：An umbrella reviewSemantic proximity
Exploring the impact of Durvalumab on biliary tract cancer- insights from real world clinical dataSemantic proximity
Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.Semantic proximity
Real-world Analysis of Treatment Patterns, Clinical Outcomes, and Molecular Profiling in Advanced Biliary Tract Cancer.Semantic proximity
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.Semantic proximity
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.Semantic proximity
Alterations in genomic features and the tumour immune microenvironment predict immunotherapy outcomes in advanced biliary tract cancer patients.Semantic proximity
Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers.Semantic proximity
Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy.Semantic proximity
Targeted Therapy Improves Real-World Survival in Patients with Molecularly Matched Advanced Biliary Tract CancerSemantic proximity
PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.Semantic proximity
Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.Semantic proximity
Select a neighboring publication to make it the new centre.